<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39193668</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-8022</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of biomaterials applications</Title><ISOAbbreviation>J Biomater Appl</ISOAbbreviation></Journal><ArticleTitle>Antibacterial activity of a silver-incorporated vancomycin-modified mesoporous silica against methicillin-resistant <i>Staphylococcus aureus</i>.</ArticleTitle><Pagination><StartPage>439</StartPage><EndPage>454</EndPage><MedlinePgn>439-454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08853282241274517</ELocationID><Abstract><AbstractText>Since conventional antibiotics are almost ineffective on methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) strains, designing their antibacterial alternatives is necessary. Besides, the use of vancomycin is applied for specific detection of the bacteria. Silver-incorporated vancomycin-modified mesoporous silica nanoparticles (MSNs@Van@Ag NPs) were designed for detection and treatment of MRSA bacteria. Mesoporous silica nanoparticles (MSNs) were synthesized through the template method, modified with vancomycin, and finally incorporated with silver nanoparticles (Ag NPs). The MSNs@Van@Ag NPs with a homogenously spherical shape, average size of 50-100 nm, surface area of 955.8 m<sup>2</sup>/g, and thermal stability up to 200°C were successfully characterized. The amount of Ag incorporated into the MSNs@Van@Ag was calculated at 3.9 ppm and the release amount of Ag was received at 2.92 ppm (75%) after 100 h. The in vitro antibacterial susceptibility test showed the MIC of 100 μg mL<sup>-1</sup> for MSNs@Van and 50 μg mL<sup>-1</sup> for MSNs@Van@Ag, showing in vitro enhanced effect of Ag and vancomycin in the bactericidal process. An in vivo acute pneumonia model was performed and biochemical assays and pathological studies confirmed the nanomedicine's short-term safety for in vivo application. Cytokine assay using ELISA showed that MSN@Van@Ag causes a reduction of pro-inflammatory cytokines and bacterial proliferation leading to alleviation of inflammatory response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chamani</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asgari</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Polymer Research Laboratory, Department of Chemistry, Sharif University of Technology, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">68260</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najmeddin</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourjavadi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Polymer Research Laboratory, Department of Chemistry, Sharif University of Technology, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">68260</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaceutical Microbiology Group, Pharmaceutical Quality Assurance Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gholami</LastName><ForeName>Mahdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Toxicology &amp; Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorkoosh</LastName><ForeName>Farid Abedin</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0002-0417-7300</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran.</Affiliation><Identifier Source="RINGGOLD">48439</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomater Appl</MedlineTA><NlmUniqueID>8813912</NlmUniqueID><ISSNLinking>0885-3282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6Q205EH1VU</RegistryNumber><NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7631-86-9</RegistryNumber><NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3M4G523W1G</RegistryNumber><NameOfSubstance UI="D012834">Silver</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055624" MajorTopicYN="Y">Methicillin-Resistant Staphylococcus aureus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014640" MajorTopicYN="Y">Vancomycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012822" MajorTopicYN="Y">Silicon Dioxide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012834" MajorTopicYN="Y">Silver</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="Y">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053768" MajorTopicYN="Y">Metal Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013203" MajorTopicYN="N">Staphylococcal Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mesoporous silica</Keyword><Keyword MajorTopicYN="N">antibacterial activity</Keyword><Keyword MajorTopicYN="N">methicillin-resistant staphylococcus aureus</Keyword><Keyword MajorTopicYN="N">silver</Keyword><Keyword MajorTopicYN="N">vancomycin</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>19</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39193668</ArticleId><ArticleId IdType="doi">10.1177/08853282241274517</ArticleId></ArticleIdList></PubmedData></PubmedArticle>